Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report)'s share price was up 7.7% on Wednesday . The company traded as high as $56.77 and last traded at $56.77. Approximately 1,136 shares traded hands during trading, a decline of 99% from the average daily volume of 97,964 shares. The stock had previously closed at $52.71.
Analyst Ratings Changes
A number of analysts have recently weighed in on PVLA shares. Canaccord Genuity Group upped their price objective on Palvella Therapeutics from $52.00 to $66.00 and gave the stock a "buy" rating in a research report on Tuesday, August 19th. HC Wainwright upped their price objective on Palvella Therapeutics from $38.00 to $75.00 and gave the stock a "buy" rating in a research report on Friday, August 15th. Raymond James Financial set a $54.00 price objective on Palvella Therapeutics and gave the stock an "outperform" rating in a research report on Tuesday, August 5th. Chardan Capital increased their target price on Palvella Therapeutics from $50.00 to $60.00 and gave the company a "buy" rating in a report on Friday, August 15th. Finally, Truist Financial assumed coverage on Palvella Therapeutics in a report on Monday, July 21st. They issued a "buy" rating and a $56.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating and ten have issued a Buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $58.50.
Check Out Our Latest Stock Analysis on PVLA
Palvella Therapeutics Stock Down 0.7%
The firm has a fifty day simple moving average of $37.39 and a 200-day simple moving average of $28.46. The company has a market cap of $578.77 million, a PE ratio of -4.32 and a beta of -0.03.
Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.08). Equities research analysts forecast that Palvella Therapeutics, Inc. will post -3.69 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Palvella Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in PVLA. Renaissance Technologies LLC purchased a new position in shares of Palvella Therapeutics during the fourth quarter worth about $256,000. Citadel Advisors LLC purchased a new position in shares of Palvella Therapeutics during the fourth quarter worth about $125,000. Cresset Asset Management LLC purchased a new position in shares of Palvella Therapeutics during the fourth quarter worth about $251,000. DAFNA Capital Management LLC purchased a new position in shares of Palvella Therapeutics during the fourth quarter worth about $857,000. Finally, Suvretta Capital Management LLC purchased a new position in shares of Palvella Therapeutics during the fourth quarter worth about $8,574,000. Hedge funds and other institutional investors own 40.11% of the company's stock.
Palvella Therapeutics Company Profile
(
Get Free Report)
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Palvella Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palvella Therapeutics wasn't on the list.
While Palvella Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
